Table 2.
Additional Treatments During Trial Follow Up.
| Intensive Management |
Standard Care |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Additional drugs | Oral MTX | Subcut MTX | SSZ | LEF | HCQ | Oral MTX | Subcut MTX | SSZ | LEF | HCQ |
| n = 68 | n = 27 | n = 31 | n = 12 | n = 29 | n = 76 | n = 21 | n = 22 | n = 11 | n = 37 | |
| None | 13 (19%) | 4 (15%) | 3 (10%) | – | 2 (7%) | 20 (26%) | 5 (24%) | 7 (32%) | 3 (27%) | – |
| One DMARDs | 23 (34%) | 12 (44%) | 12 (39%) | 3 (25%) | 5 (17%) | 33 (43%) | 12 (57%) | 9 (41%) | 5 (45%) | 18 (49%) |
| Two DMARDs | 13 (19%) | 6 (22%) | 11 (35%) | 5 (33%) | 9 (31%) | 14 (18%) | 1 (5%) | 5 (23%) | – | 11 (30%) |
| Etanercept | 16 (24%) | 4 (15%) | 4 (13%) | 4 (42%) | 9 (31%) | 4 (5%) | 1 (5%) | 1 (4%) | 2 (18%) | 4 (11%) |
| Benepali | 1 (1%) | 1 (4%) | 1 (3%) | – | 1 (4%) | 2 (3%) | – | – | – | – |
| Other TNF Inhibitor | 2 (3%) | – | – | – | 3 (10%) | 3 (4%) | 2 (10%) | – | 1 (9%) | 4 (11%) |
Patient who had Azathioprine at baseline also had additional HCQ; SSZ= Sulfasalazine; HCQ= Hydroxychloroquine; MTX= methotrexate; LEF= Leflunomide; DMARD=disease-modifying antirheumatic drugs.